Patients with obesity achieved 6.45% weight loss at three months and 11.35% weight loss at six months using submaximal doses of semaglutide, accompanied by meaningful reductions in waist circumference (13 cm total) and BMI (from 40.3 to 35.5 kg/m²). The 56-patient cohort demonstrated these outcomes occurred below maximum approved dosing levels. This finding challenges the assumption that maximum therapeutic doses are necessary for clinically meaningful weight loss with GLP-1 receptor agonists. The results suggest a more nuanced dosing approach could improve treatment accessibility and reduce side effects while maintaining efficacy. However, the observational design limits causal interpretation, and the relatively small sample size warrants caution in generalizing findings. The study lacks comparison to standard maximum-dose protocols, making it difficult to assess whether submaximal dosing represents optimal therapy or simply adequate outcomes. For obesity management, this represents an incremental but practically significant finding that could influence prescribing patterns, particularly given semaglutide's cost and supply constraints, though longer-term data on weight maintenance and metabolic benefits remain essential.